Names and pronunciation
(tur-luh-preh-sn) Terlivaz
Source page 1417
Loading InternPractice…
Individual generic drug information
Extracted information for terlipressin only.
(tur-luh-preh-sn) Terlivaz
Source page 1417
Func. class.: Pituitary hormone
Source page 1417
Chem. class.: Vasopressin receptor agonist ACTIONS: A vasopressin receptor agonist indicated to improve kidney func- tion in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function
Source page 1417
USES: Hepatorenal syndrome
Source page 1417
Extracted information for terlipressin only.
CONTRAINDICATIONS Acute myocardial ischemia, bowel isch- emia, hypoxia, peripheral vascular ischemia
Source page 1417
Black Box Warning: Acute-on-chronic liver failure, respiratory failure Precautions: Volume overload, preg- nancy, breastfeeding, liver failure, liver transplant
Source page 1417
INTERACTIONS None known NURSING CONSIDERATIONS
Source page 1418
Extracted information for terlipressin only.
DOSAGE AND ROUTES Adult: IV Days 1-3 0.85 mg (1 vial) q6hr; day 4 assess serum creatinine vs. base- line, if serum creatinine has decreased by ≥30% continue 0.85 mg (1 vial) q6hr; if serum creatinine has decreased by <30% give 1.7 mg (2 vials) q6hr; if no change in serum creatinine discontinue; continue until 24 hr after 2 consecutive serum creatinine tests <1.5 mg/dL at least 2 hr apart, max 14 days
Source page 1417
Available forms: Lyophilized powder for single dose IV 0.85 mg/vial
Source page 1417
Administer: • Reconstitute each vial with 5 mL of 0.9% NaCl injection for a 0.85 mg/5 mL solution • Visually inspect for particulate matter and discoloration prior to administration • Prior to initial dosing, assess patient for ACLF grade 3 and obtain patient base- line oxygenation level. Monitor patient oxygen saturation with pulse • Intermittent IV push route • Give by slow IV bolus over 2 min • Administer through a peripheral or central line. A dedicated central line is not required • Flush the line after use • If not used immediately, store at 36°F to 46°F (2°C to 8°C) for up to 48 hr, do not freeze. The reconstituted solution does not need protection from light
Source pages 1417, 1418
Extracted information for terlipressin only.
Assess: • Oxygen saturation (SpO2) prior to starting treatment; do not start in persons experiencing hypoxia (SpO2 <90%) until improvement of oxygen saturation oc- curs • Monitor for changes in respiratory status, including hypoxia, during therapy using continuous pulse oximetry and regular clinical assessments • Discontinue if SpO2 decreases below 90% or if increased respiratory symp- toms occur • Pregnancy/breastfeeding: not to be used, as fetal harm may occur
Source page 1418
Evaluate: • Positive therapeutic outcome
Source page 1418
Patient and caregiver information: • Pregnancy/breastfeeding: to notify provider if pregnancy is planned or sus- pected or if breastfeeding. Not to be used in pregnancy and breastfeeding, effects are unknown
Source page 1418
Extracted information for terlipressin only.
PHARMACOKINETICS Terminal half-life 0.9 hr, lysine 3 hr, max change in B/P and heart rate is 1.2-2 hr
Source page 1418
Filter the extracted dose blocks for this individual drug.